Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis

Sho Mokuda, Yosuke Murata, Naoya Sawada, Kenichiro Matoba, Akihiro Yamada, Makoto Onishi, Yasuaki Okuda, Kazuo Jouyama, Eiji Sugiyama and Kiyoshi Takasugi

PLOS ONE, 2013, vol. 8, issue 8, 1-6

Abstract: Factor XIII is one of the twelve coagulation factors and also known as a fibrin-stabilizing factor. In 2012, we encountered a male RA patient with hemorrhagic factor XIII deficiency who had been treated with tocilizumab for two years. There are few reports regarding the relationship between tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R)) and factor XIII. We measured the factor XIII activity levels in the plasma of 40 RA patients (10 patients treated without biologics, 30 patients treated with biologics (15 patients treated with necrosis factor inhibitors and 15 patients treated with tocilizumab)) and 19 healthy controls. Consequently, the tocilizumab group exhibited lower levels than the other three groups according to the Steel-Dwass test (P

Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069944 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 69944&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0069944

DOI: 10.1371/journal.pone.0069944

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().